This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Clariant investor secures German clearance to boost stake to at least 25 percent

( December 15, 2017, 17:00 GMT | Official Statement) -- MLex Summary: A top Clariant shareholder has received German competition approval to boost its interest in the Swiss specialty chemical maker to at least 25 percent. The clearance allows 40 North Latitude Master Fund to increase its shares and voting rights in Clariant by at least 4 percent, potentially taking its combined stake with a partnership called White Tale to at least 25 percent. The decision comes as White Tale is locked in a stalemate with Clariant, which has rejected the investor’s demands for three board seats and an independent strategy review. 29.11.2017 B3-177/17 40 North La­ti­tu­de Mas­ter Fund Ltd., Ca­y­man In­seln; Er­werb wei­te­rer Ka­pi­talan­tei­le und Stimm­rech­te von min­des­tens 4% auf ins­ge­samt min­des­tens 25 % an der Cla­ri­ant Ltd., Mut­tenz, Schweiz; Ad­di­ti­ve, Azo-Pig­men­te, Fließ­ver­bes­se­rer für Heiz­öl, Pro­zess- und Um­welt­ka­ta­ly­sa­to­ren - 13.12.2017 (Frei­ga­be)...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login